Pfizer Inc has made the strategic decision to consolidate its manufacturing operations and is offering its Bristol, Tennessee, manufacturing site for sale. This site is comprised of approximately 400,000 square feet of manufacturing and office space on 9 acres and is focused on the manufacture of oral solid dosage products including tablets and capsules and semi-solids.

The Opportunity:

The site is located in Bristol, Tennessee, 20 minutes drive from the Tri-Cities airport and approximately 120 miles from Knoxville. The facility currently produces a range of products that primarily service the US market. Acquisition of the Bristol site would provide:

- Capability to manufacture controlled substances (Schedule II and III) including vault storage.
- Five manufacturing suites for the production of small molecule solids, hormonal solids, controlled solids, and creams / ointments.
- Three high speed bottle packaging lines for tablets and capsules and a tube / jar filling line.
- Analytical and microbiological laboratories.
- A new pilot plant for the development of new Schedule II controlled products.
- Office facilities suitable for corporate headquarters operations.
- Access to a skilled Life Sciences work force.
- Excellent site infrastructure.
- Facilities with an excellent regulatory approval record.
- A trailing product supply agreement.
Annual manufacturing capacity of 3.5 billion tablets and 700 million capsules.

Annual capacity of 138,000 Kg of bulk creams and ointments and 5.3 million tubes / jars.

Three bottle packaging lines with speeds of 50-100 bottles per minute and a capacity of 43 million bottles per year.

Over $30 million has been invested in the site over the past four years to upgrade and add new manufacturing and support facilities including:

- Vaults for the storage of DEA Schedule II products.
- Improvements to the creams / ointments manufacturing areas.
- A new pilot plant to support development work on new DEA Schedule II oral solid dosage products which includes down flow booths, formulation, mixing, blending, encapsulation, capsule sealing and check weighing.
- Commercial scale manufacturing space / equipment to support newly developed DEA Schedule II products.
- Additional formulation and tableting capacity.

Approximately 70,000 SF of general warehouse storage and 7,400 SF of controlled substances storage.

---

For further information, please contact:

**Charlie Shafran**  
Project Leader  
Cell: 917.821.7693  
cshafran@pharmabiosource.com

**Bill Wiederseim**  
Technical Information  
Cell: 610.888.9806  
wiederseim@pharmabiosource.com

No representation or warranty, express or implied, is given by Pfizer or their respective advisers or any of their respective directors, employees or contractors or any other person as to the accuracy or completeness of the contents of this summary information. The only representations and warranties that will be made are those that may eventually be included in a definitive agreement for the proposed transaction, if any. Neither this summary nor any of the information contained in it shall form the basis of an offer to purchase or acquire any shares, assets or interest in the facility.